Fujian Haixi Pharmaceuticals Co., Ltd. (“Haixi Pharma”) has issued the proxy form and full agenda for its annual general meeting scheduled for 10:00 a.m. on 27 May 2026 at the company’s headquarters in Fuzhou, Fujian Province.

The meeting will put 18 resolutions to a shareholder vote, comprising 14 ordinary and four special items:

1. 2025 operating matters • Board and Supervisory Board work reports. • Audited consolidated financial statements and independent auditor’s report. • 2025 annual report together with the ESG report. • Final accounts and profit-distribution plan for 2025.

2. Corporate governance and remuneration • Re-appointment of external auditor for 2026 with authority for the Board to determine fees. • Directors’ remuneration for 2026. • Application for 2026 bank credit facilities and related guarantees.

3. Structural changes • Proposal to abolish the existing Board of Supervisors. • Amendments to the Rules of Procedure for both the Shareholders’ Meetings and the Board of Directors.

4. Board composition • Election of nine directors for the second Board session, including five executive, two non-executive and two independent non-executive candidates.

5. Capital allocation • Capital increase for the Hong Kong subsidiary.

Special resolutions require a two-thirds majority of votes cast: • Amendments to the Articles of Association. • Introduction of a share-incentive implementation plan. • Renewal of the general mandate to issue shares. • Renewal of the mandate to repurchase shares.

Shareholders unable to attend in person may appoint a proxy; duly completed forms, together with any notarised authorisations, must reach Tricor Investor Services Limited by 10:00 a.m. on 26 May 2026 to be valid.